DEXRAZOXANE (dex-ra-zox'ane) Zinecard Classifications: chelating agent; chemoprotective agent; cardioprotective for doxorubicin; Therapeutic: cardioprotective for doxorubicin Pregnancy Category: C |
250 mg, 500 mg vials for injection
A derivative of EDTA that readily penetrates cell membranes. Dexrazoxane is converted intracellularly to a chelating agent that interferes with iron-mediated free radical generation thought to be partially responsible for one form of cardiomyopathy.
Cardioprotective effect is related to its chelating activity.
Reduction of cardiomyopathy associated with a cumulative doxorubicin dose of 300 mg/m2.
Chemotherapy regimens that do not contain anthracycline, pregnancy (category C), lactation.
Myelosuppression, elderly; prior radiation or chemotherapy; renal failure or impairment. Safety and efficacy in children have not been established.
Cardiomyopathy Adult: IV 10 parts dexrazoxane to 1 part doxorubicin or 500 mg/m2 for every 50 mg/m2 of doxorubicin Renal Impairment Clcr <40 mL/min: use a 5:1 ratio of dexrazoxane to doxorubicin |
Intravenous
PREPARE: Direct: Reconstitute by adding 25 or 50 mL of 0.167 M sodium lactate injection (provided by manufacturer) to the 250- or 500-mg vial, respectively, to produce a 10-mg/mL solution. IV Infusion: Further dilute with NS or D5W in an IV bag to a concentration of 1.35.0 mg/mL for infusion. ADMINISTER: Direct: Give slow IV push. IV Infusion: Give over 10 min. |
Assessment & Drug Effects
Patient & Family Education